Skip to main navigation Skip to search Skip to main content

Nivolumab plus ipilimumab in advanced non-small-cell lung cancer

  • M. D. Hellmann
  • , L. Paz Ares
  • , R. Bernabe Caro
  • , B. Zurawski
  • , S. W. Kim
  • , E. Carcereny Costa
  • , K. Park
  • , A. Alexandru
  • , L. Lupinacci
  • , E. De La Mora Jimenez
  • , H. Sakai
  • , I. Albert
  • , A. Vergnenegre
  • , S. Peters
  • , K. Syrigos
  • , F. Barlesi
  • , M. Reck
  • , H. Borghaei
  • , J. R. Brahmer
  • , K. J. O fByrn
  • W. J. Geese, P. Bhagavatheeswaran, S. K. Rabindran, R. S. Kasinathan, F. E. Nathan, S. S. Ramalingam
  • Memorial Sloan-Kettering Cancer Center
  • Hospital Universitario 12 de Octubre
  • Hospital Universitario Virgen del Rocio
  • Ambulatorium Chemioterapii
  • Generalitat de Catalunya
  • Sungkyunkwan University
  • Oncology Institute Professor Doctor Alexandru Trestioreanu
  • Hospital Italiano de Buenos Aires
  • Instituto Jalisciense de Cancerologia
  • Saitama Cancer Center
  • Matrai Gyogyintezet
  • CHU de Limoges
  • University of Lausanne
  • National and Kapodistrian University of Athens
  • Aix-Marseille University
  • German Center of Lung Research
  • Fox Chase Cancer Center
  • Johns Hopkins University
  • Princess Alexandra Hospital
  • Bristol-Myers Squibb
  • Emory University

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Nivolumab plus ipilimumab in advanced non-small-cell lung cancer'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science